Features of patients who developed hepatocellular carcinoma after direct-acting antiviral treatment for hepatitis C Virus

BackgroundThe features of hepatitis C virus patients with a sustained virologic response (SVR) who developed hepatocellular carcinoma (HCC) after direct-acting antiviral (DAA) therapy are unclear.MethodsThe study population included 1494 DAA-SVR patients without a history of HCC. The cumulative carc...

Full description

Saved in:
Bibliographic Details
Published in:PloS one 2022-01, Vol.17 (1), p.e0262267
Main Authors: Seiichi Mawatari, Kotaro Kumagai, Kohei Oda, Kazuaki Tabu, Sho Ijuin, Kunio Fujisaki, Shuzo Tashima, Yukiko Inada, Hirofumi Uto, Akiko Saisyoji, Yasunari Hiramine, Masafumi Hashiguchi, Tsutomu Tamai, Takeshi Hori, Ohki Taniyama, Ai Toyodome, Haruka Sakae, Takeshi Kure, Kazuhiro Sakurai, Akihiro Moriuchi, Shuji Kanmura, Akio Ido
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:BackgroundThe features of hepatitis C virus patients with a sustained virologic response (SVR) who developed hepatocellular carcinoma (HCC) after direct-acting antiviral (DAA) therapy are unclear.MethodsThe study population included 1494 DAA-SVR patients without a history of HCC. The cumulative carcinogenesis rate after the end of treatment (EOT) and factors related to HCC were analyzed.ResultsSixty (4.0%) patients developed HCC during a median observation period of 47.6 months. At four years, the cumulative carcinogenesis rate was 4.7%. A Cox proportional hazards analysis showed that age ≥73 years (hazard ratio [HR]: 2.148), male sex (HR: 3.060), hyaluronic acid (HA) ≥75 ng/mL (HR: 3.996), alpha-fetoprotein at EOT (EOT-AFP) ≥5.3 ng/mL (HR: 4.773), and albumin at EOT (EOT-Alb)
ISSN:1932-6203
DOI:10.1371/journal.pone.0262267